Received 14/09/2023
DOI: 10.35556/idr-2023-4(105)10-15

Modern understanding of the problem of bisphosphonate osteonecrosis of the jaws
Khelminskaya N.M.1, ORCID ID: 0000-0002-3627-9109, Posadskaya A.V.1, ORCID ID: 0000-0002-5926-8541, Vinokurova L.M.1, ORCID ID: 0009-0005-6889-6979, Kravets V.I.1, ORCID ID: 0000-0002-6345-3993, Eremin D.A.1, ORCID ID: 0000-0003-4077-6359, Cherepanova E.V.1, ORCID ID: 0000-0004-8742-4937, Kovalenko C.N.2 ORCID ID: 0009-0006-4221-7349
1Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation117997, Russia, Moscow, Ostrovityanova st., 1
2Moscow Pirogov City Clinical Hospital №1
119049, Russia, Moscow, Leninsky Prospekt, 8

Summary
The article is devoted to the concept of osteonecrosis formation in oncological patients with bone metastases taking bisphosphonate preparations. The significance of the problem of bisphosphonate osteonecrosis of the jaws is associated with an increase in the number of such patients over the past few decades, a high frequency of complications and relapses, and a negative prognosis of the disease. The number of inflammatory lesions of the jaws when using bisphosphonate preparations can reach 25% of the total number of patients, the number of abscesses and phlegmon reaches 45%. The article considers risk factors, the frequency of inflammatory lesions of the jaw bones, known approaches to the diagnosis and treatment of drug-associated osteonecrosis of the jaws.

Keywords: bisphosphonates, oncology, metastatic cancer, osteonecrosis, jaw.

For citation: Khelminskaya N.M., Posadskaya A.V., Vinokurova L.M., Kravets V.I., Eremin D.A., Cherepanova E.V., Kovalenko C.N. Modern understanding of the problem of bisphosphonate osteonecrosis of the jaws. Stomatology for All / Int. Dental Review. 2023; no.4(105): 10-15(In Russian). doi: 10.35556/idr-2023-4(105)10-15

Литература
1. Валиева М.М. Ранняя диагностика бисфосфонатных остеонекрозов челюстей, Практическая медицина. – 2018. – 7 (2). – С. 26–29 [Valieva M.M. Early diagnosis of bisphosphonate osteonecrosis of the jaws, Practical medicine. – 2018. – 7 (2). – p. 26-29] 2. Виноградова Н.Г. Распространенность и клинические особенности медикаментозно ассоциированных остеонекрозов челюстей, Проблемы стоматологии. – 2017. – 12 (4). – С. 38-42 [Vinogradova N.G. Prevalence and clinical features of drug-associated osteonecrosis of the jaws, Problems of dentistry. – 2017. – 12 (4). – p. 38-42] 3. Заславская, H.A. Проблемы своевременной диагностики и лечения остеонекрозов челюстей у больных злокачественными новообразованиями, получающих антирезорбтивную терапию [Текст] / H.A. Заславская, А.Ю. Дробышев, А.Г. Волков, Д.А. Лежнев, Н.Ж. Дикопова // XXI Российский национальный конгресс «Человек и лекарство»: сборн. мат. контр, (тезисы докл.). – М., 2014. – С. 131. [Zaslavskaya, H.A. Problems of timely diagnosis and treatment of osteonecrosis of the jaws in patients with malignant neoplasms receiving antiresorptive therapy [Text] / H.A. Zaslavskaya, A.Y. Drobyshev, A.G. Volkov, D.A. Lezhnev, N.Z. Dikopova // XXI Russian National Congress “Man and Medicine”: collection. mat. counter, (abstracts). – M., 2014. – p. 131.] 4. Жукова Н. А. Стадирование бисфосфонатного остеонекроза челюстей у больных злокачественными новообразованиями по данным мультисрезовой компьютерной томографии. Мед. визуализация. 2016; (3). С.17–27 [Zhukova N. A. Staging of bisphosphonate osteonecrosis of the jaws in patients with malignant neoplasms according to multisection computed tomography. Med. visualization. 2016; (3). p.17–27] 5. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2022. илл. − 252 с. [Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2021 (morbidity and mortality) – Moscow: P.A. Herzen Institute of Medical Research − Branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, − 2022. fig. − 252 p.] 6. Коржевский Д. Э, Гиляров А. В. Основы гистологической техники, СПб. : Спецлит, 2010. – С. 32–46 [Korzhevsky D. E., Gilyarov A.V. Fundamentals of histological technique, St. Petersburg : Spetslit, 2010. – p. 32-46] 7. Лебедев М.В. Бисфосфонатные остеонекрозы челюстей как осложнение химиотерапетического лечения при злокачественных процессах, Уральский медицинский журнал. – 2020, №7 (190) – С. 115-120 [Lebedev M.V. Bisphosphonate osteonecrosis of the jaws as a complication of chemotherapeutic treatment in malignant processes, Ural Medical Journal. – 2020, №7 (190) – p. 115-120] 8. Митрофанова Н.И. К вопросу антибиотикорезистентности этиологических агентов гнойно-воспалительных заболеваний у пациентов отделений челюстно-лицевой хирургии многопрофильного стационара, Известия высших учебных заведений. – 2017. №3 – С. 43-48 [Mitrofanova N.I. On the issue of antibiotic resistance of etiological agents of purulent-inflammatory diseases in patients of maxillofacial surgery departments of a multidisciplinary hospital, Proceedings of higher educational institutions. – 2017. No.3 – pp. 43-48] 9. Снеговой А.В., Кононенко И.Б. Современные возможности остеомодифицирующей терапии при метастазах в кости. РМЖ. Медицинское обозрение. 2019;27(6):16-22. [Snegovoi A.V., Kononenko I.B. Modern possibilities of osteomodifying therapy for bone metastases. RMJ. Medical Review. 2019;27(6):16-22.] 10. Спевак, Е.М. Бисфосфонатные остеонекрозы челюстей: современное состояние проблемы, Казанский медицинский журнал – 2017. (1). – С. 46-52
[Spevak, E.M. Bisphosphonate osteonecrosis of the jaws: current state of the problem, Kazan Medical Journal – 2017. (1). – p. 46-52] 11. Малышева Ю.В., Тихомирова И.А., Петроченко Е.П. Изменения реологии крови и функциональных свойств тромбоцитов при злокачественных новообразованиях почек, Журнал медико-биологических исследований. 2018. Т. 6, № 4.- С. 348–358 [Malysheva Yu.V., Tikhomirova I.A., Petrochenko E.P. Changes in blood rheology and functional properties of platelets in malignant neoplasms of the kidneys, Journal of Biomedical Research. 2018. vol. 6, No. 4.- p. 348-358] 12. Масляков В. В., Власенко Ю. Б., Ким Л. М. Реологические свойства крови при базально-клеточном раке кожи в ближайшем послеоперационном периоде, Медицинские науки. Клиническая медицина. – № 3 (39), 2016. – С.53-61 [Maslyakov V. V., Vlasenko Yu. B., Kim L. M. Rheological properties of blood in basal cell skin cancer in the immediate postoperative period, Medical sciences. Clinical medicine. – № 3 (39), 2016. p.53-61] 13. Эбзеев А.К. Бисфосфонатный остеонекроз челюстей у онкологических пациентов. Казанский мед. ж. 2020; 101 (2): 226–231. [Ebzeev A.K. Bisphosphonate osteonecrosis of the jaws in cancer patients. Kazan Medical Journal. 2020; 101(2):226–231.] 14. Amadori D., Aglietta M., Alessi B., Gianni L., Ibrahim T., Farina G., Gaion F., Bertoldo F., Santini D., Rondena R. et al (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer: a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663–670. doi:10. 1016/S1470-2045(13)70174-8].
15. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.011
16. Blus C., Giannelli G., Szmukler-Moncler S., Orru G. Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites. Oral Maxillofac. Surg. 2017; 21 (1): 41–17. Bonacina R, Mariani U, Villa F, et al. Osteonecrosis of the jaw in patients treated with bisphosphonates: a review of the literature and a comprehensive treatment algorithm. Int J Dent. 2018;2018:8175476. doi: 10.1155/2018/8175476
18. Coxon, F.P., Thompson, K., Roelofs, A.J., Ebetino, F.H. and Rogers, M.J. (2008) Visualizing Mineral Binding and Uptake of Bisphosphonate by Osteoclasts and Non-Resorbing Cells. Bone, 42, 848-860. doi:10.1016/j.bone.2007.12.225
19. Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F., Reid I.R., Ruggiero S.L., Taguchi A., Tetradis S. et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23. doi:10.1002/jbmr.2405
20. Khan AA, Sandor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008;35(7):1391-1397. doi:10.3899/jrheum.080320
21. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-1117. doi: 10.1016/s0278-2391(03)00720-1
22. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415-423. doi: 10.1016/j.joms.2006.06.284.
23. McGowan K, McGowan T, S Ivanovski Risk factors for medication-related osteonecrosis of the jaws: A systematic review First published: 28 June 2017 doi:10.1111/odi.12708 Oral Diseases Volume 24, Issue 4 p. 527-536
24. Migliorati CA. Bisphosphonate-associated osteonecrosis: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):285-290. doi: 10.1016/j.tripleo.2005.05.015.
25. Mustakim KR, Eo MY, Lee JY, Seo MH, Kim SM. Clinical significance of drug cessation on medication- related osteonecrosis of the jaw in patients with osteoporosis. J Korean Assoc Oral Maxillofac Surg 2023;49:75-85. doi:10.5125/jkaoms.2023.49.2.75
26. Mücke, T., Deppe, H., Hein, J., Wolff, K. D., Mitchell, D. A., Kesting, M. R., & Thalgott, M. (2016). Prevention of bisphosphonate-related osteonecro- sis of the jaws in patients with prostate cancer treated with zoledronic acid – A prospective study over 6 years. Journal of Cranio-Maxillofacial Surgery, 44(10), 1689–1693.
27. Owosho A. A., Estilo C. L., Huryn J. M. et al. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016; 122 (4): 455–459.
28. Poli P. P., Souza F. A., Maiorana C. Adjunctive use of antimicrobial photodynamic therapy in the treatment of medication-related osteonecrosis of the jaws: A case report. Photodiagnosis Photodyn. Ther. 2018; 23: 99–101.
29. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72:1938–56. doi:10.1016/j.joms.2014.04.031
30. Sarasquete, M.E., Garcia-Sanz, R., Marin, L., Alcoceba, M., Chillon, M.C., Balanzategui, A., Santamaria, C., Rosinol, L., de la Rubia, J., Hernandez, M.T., Garcia-Navarro, I., Lahuerta, J.J., Gonzalez, M., San Miguel, J.F., 2008. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 112, 2709–2712.
31. Voss P. J., Matsumoto A., Alvarado E. et al. Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. Odontology. 2017; 105 (4): 484–493.